不同口服抗凝药与房颤患者肾功能恶化的关联:多中心队列研究
该多中心前瞻性队列纳入1667例非瓣膜性房颤患者,比较VKA与NOAC对eGFR年下降中位数的影响。VKA组eGFR下降-2.11,达比加群、利伐沙班和阿哌沙班组下降更少;NOAC组eGFR降至<50 mL/min/1.73 m2的风险更低,但该关联在糖尿病患者中明显减弱。
要点
- NOAC组eGFR年下降中位数小于VKA组,达比加群、利伐沙班和阿哌沙班均优于VKA。
- 达比加群和阿哌沙班患者eGFR降至<50 mL/min/1.73 m2的风险显著低于VKA。
- NOAC对肾功能下降的保护作用在糖尿病患者中明显减弱。
核心结论
- 与VKA相比,NOAC组肾功能下降更慢,但该效应在糖尿病患者中部分消失。
研究设计与样本
- 多中心前瞻性队列研究,纳入1667例非瓣膜性房颤患者,VKA组743例,NOAC组924例。
- 基线及随访期用CKD-EPI公式评估eGFR,主要终点为eGFR年下降中位数。
主要发现
- VKA组eGFR年下降中位数为-2.11(IQR -5.68/-0.62)。
- 达比加群组eGFR年下降中位数为-0.27(IQR -9.00/4.54,P<0.001 vs VKA)。
- 利伐沙班组eGFR年下降中位数为-1.21(IQR -9.98/4.02,P=0.004 vs VKA)。
- 阿哌沙班组eGFR年下降中位数为-1.32(IQR -8.70/3.99,P=0.003 vs VKA)。
关键数值与推荐
- eGFR降至<50 mL/min/1.73 m2的比值比:达比加群OR 0.492(95%CI 0.298-0.813,P=0.006),阿哌沙班OR 0.449(95%CI 0.276-0.728,P=0.001)。
- 所有NOAC组eGFR分级恶化的发生率均低于VKA组。
- NOAC标准剂量与减剂量之间未发现差异。
临床怎么用
- 房颤患者选用NOAC可能有助于减缓肾功能下降,尤其达比加群和阿哌沙班。
- 合并糖尿病的房颤患者中NOAC对肾功能的保护作用可能减弱,需更密切监测肾功能。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: To investigate the decline of estimated glomerular filtration rate (eGFR) in patients with atrial fibrillation (AF) treated with vitamin K antagonists (VKAs) or non-VKA oral anticoagulants (NOACs). METHODS: Multicentre prospective cohort study including 1667 patients with nonvalvular AF. The eGFR was assessed by the CKD-EPI formula at baseline and during follow-up. The primary endpoint of the study was the median annual decline of eGFR according to VKA (n = 743) or NOAC (n = 924) use. As secondary endpoints, we analysed the transition to eGFR <50 mL/min/1.73 m2 and the eGFR class worsening. RESULTS: Median age was 73.7 ± 9.1 years and 43.3% were women. VKA-treated patients showed an eGFR decline of -2.11 (interquartile range [IQR] -5.68/-0.62), which was -0.27 (IQR -9.00/4.54, P < 0.001 vs VKAs), -1.21 (IQR -9.98/4.02, P = 0.004 vs VKAs) and -1.32 (IQR -8.70/3.99, P = 0.003 vs VKAs) in patients on dabigatran, rivaroxaban and apixaban, respectively. Transition to eGFR <50 mL/min/1.73 m2 was lower in dabigatran- and apixaban-treated patients: odds ratio (OR) 0.492, 95% confidence interval (CI) 0.298-0.813, P = 0.006 and OR 0.449, 95% CI 0.276-0.728, P = 0.001, respectively. A lower rate of eGFR class worsening was found in all groups of NOACs compared to VKAs. No difference between full and reduced dose of NOAC was found. Subgroup analysis showed that the association between NOAC and eGFR changes was markedly reduced in diabetic patients. CONCLUSION: Patients prescribed NOACs showed a lower decline of renal function compared to those prescribed VKAs. This effect was partially lost in patients with diabetes.
引用
- Pastori D, Ettorre E, Lip GYH, et al. Association of different oral anticoagulants use with renal function worsening in patients with atrial fibrillation: A multicentre cohort study. Br J Clin Pharmacol. 2020. PMID: 32384178. doi:10.1111/bcp.14350
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。